| Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
| Insulin biphasic lispro 25/75 100u/mL injection solution 3mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
|
| Product containing insulin lispro biphasic |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
|
| Insulin biphasic lispro 25/75 100u/mL injection solution 3mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
|
| Insulin biphasic lispro 50/50 100u/mL injection solution 3mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
|
| Product containing insulin lispro and insulin lispro protamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
1 |
| Insulin lispro protamine only product |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
1 |
| Product containing precisely insulin lispro 25 unit/1 milliliter and insulin lispro protamine 75 unit/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely insulin lispro 25 unit/1 milliliter and insulin lispro protamine 75 unit/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely insulin lispro 50 unit/1 milliliter and insulin lispro protamine 50 unit/1 milliliter conventional release solution for injection (clinical drug) |
This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing precisely insulin lispro 50 unit/1 milliliter and insulin lispro protamine 50 unit/1 milliliter conventional release solution for injection (clinical drug) |
The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration). |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing only insulin lispro and insulin lispro protamine (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing insulin lispro and insulin lispro protamine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
| Product containing only insulin lispro and insulin lispro protamine in parenteral dose form (medicinal product form) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Insulin lispro protamine (substance) |
Inferred relationship |
Some |
2 |
FHIR
© HL7.org
|
Server Home |
FHIR Server FHIR Server 3.7.22-SNAPSHOT
|
FHIR Version n/a
User: [n/a]